{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T12:40:13Z","timestamp":1790944813693,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1016\/j.jconrel.2006.08.004","type":"journal-article","created":{"date-parts":[[2006,8,12]],"date-time":"2006-08-12T11:09:25Z","timestamp":1155380965000},"page":"183-188","source":"Crossref","is-referenced-by-count":37,"title":["Improved nasal absorption of salmon calcitonin by powdery formulation with N-acetyl-l-cysteine as a mucolytic agent"],"prefix":"10.1016","volume":"115","author":[{"given":"Takahiro","family":"Matsuyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Horikiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yamahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2006.08.004_bib1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0169-409X(97)00060-4","article-title":"Intranasal drug delivery","volume":"29","author":"Husaain","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2006.08.004_bib2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2165\/00003088-198917050-00001","article-title":"Intranasal drug delivery: potential advantages and limitations from a clinical pharmacokinetic perspective","volume":"17","author":"Pontiroli","year":"1989","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2006.08.004_bib3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0169-409X(97)00062-8","article-title":"Peptide hormones: review of current and emerging uses by nasal delivery","volume":"29","author":"Pontiroli","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2006.08.004_bib4","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/0006-291X(85)91224-0","article-title":"Hydrolysis of leucine enkephalin in the nasal cavity of the rat\u2014a possible factor in the low bioavailability of nasally administered peptides","volume":"133","author":"Hussain","year":"1985","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2006.08.004_bib5","first-page":"69","article-title":"Enzymatic barriers to peptide and protein absorption","volume":"5","author":"Lee","year":"1988","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"key":"10.1016\/j.jconrel.2006.08.004_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/A:1018911206646","article-title":"Drug metabolism in the nasal mucosa","volume":"9","author":"Sarkar","year":"1992","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2006.08.004_bib7","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2165\/00003088-200342130-00003","article-title":"Absorption enhancers for nasal dug delivery","volume":"42","author":"Davis","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jconrel.2006.08.004_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0169-409X(98)00054-4","article-title":"Cyclodextrins in nasal drug delivery","volume":"36","author":"Merkus","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2006.08.004_bib9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0928-0987(01)00146-4","article-title":"Nasal bioavailability of peptide T in rabbits: absorption enhancement by sodium glycocholate and glycofuro","volume":"14","author":"Bagger","year":"2001","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2006.08.004_bib10","series-title":"Drug permeation Enhancement, Theory and Application","first-page":"345","article-title":"Toxicological Evaluation of Intranasal Peptide and Protein Drugs","author":"Dorado","year":"1994"},{"key":"10.1016\/j.jconrel.2006.08.004_bib11","first-page":"91","article-title":"Mucosal penetration enhancers for facilitation of peptide and protein drug absorption","volume":"8","author":"Lee","year":"1991","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"key":"10.1016\/j.jconrel.2006.08.004_bib12","first-page":"347","article-title":"Enhancement of nasal absorption of large molecular weight compounds by combination of mucolytic agent and nonionic surfactant","volume":"110","author":"Matsuyama","year":"2006","journal-title":"J. Contemp. Relig."},{"key":"10.1016\/j.jconrel.2006.08.004_bib13","unstructured":"Package insert, Mucomyst\u00ae (acetylcysteine solution, USP), Apothecon, revised January 2001."},{"key":"10.1016\/j.jconrel.2006.08.004_bib14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/BF00558516","article-title":"Nasal administration of glucagon and human calcitonin to healthy subjects: a comparison of powders and spray solutions and of different enhancing agents","volume":"37","author":"Pontiroli","year":"1989","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2006.08.004_bib15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0378-5173(01)00930-9","article-title":"Nasal glucagon delivery using microcrystalline cellulose in healthy volunteers","volume":"233","author":"Teshima","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2006.08.004_bib16","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1023\/A:1018999414088","article-title":"Nasal insulin delivery with dimethyl-beta-cyclodextrin as an absorption enhancer in rabbits: powder more effective than liquid formulations","volume":"10","author":"Shipper","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2006.08.004_bib17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0378-5173(01)00736-0","article-title":"Improved nasal bioavailability of elcatonin by insoluble powder formulation","volume":"224","author":"Ishikawa","year":"2001","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2006.08.004_bib18","first-page":"101","article-title":"Mucosal drug delivery using cellulose derivatives as a functional polymer","volume":"62","author":"Suzuki","year":"1999","journal-title":"J. Contemp. Relig."},{"key":"10.1016\/j.jconrel.2006.08.004_bib19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0378-5173(02)00555-0","article-title":"Influence of multiple nasal administrations of bioadhesive powders on the insulin bioavailability","volume":"250","author":"Callens","year":"2003","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2006.08.004_bib20","first-page":"E19","article-title":"Formulation of a dry powder influenza vaccine for nasal delivery","volume":"10","author":"Garmise","year":"2006","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2006.08.004_bib21","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1023\/A:1016099516757","article-title":"Delivery of nasal powders of beta-cyclodextrin by insufflation","volume":"13","author":"De Ascentiis","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2006.08.004_bib22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0169-409X(97)00067-7","article-title":"Nasal delivery systems and their effect on deposition and absorption","volume":"29","author":"Kublik","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2006.08.004_bib23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0378-5173(81)90010-7","article-title":"Mechanisms for the enhancement of the nasal absorption of insulin by surfactants","volume":"9","author":"Hirai","year":"1981","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2006.08.004_bib24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0378-5173(01)00662-7","article-title":"Effect of additives on insulin absorption from intratracheally administered dry powders in rats","volume":"220","author":"Todo","year":"2001","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2006.08.004_bib25","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1248\/bpb.22.1089","article-title":"Evaluation of bile acids and fusidate derivative as nasal absorption enhancers using an electrophysiological technique","volume":"22","author":"Hosoya","year":"1999","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.jconrel.2006.08.004_bib26","first-page":"211","article-title":"Delivery systems for penetration enhancement of peptide and protein drugs: Design considerations","volume":"46","author":"Kompella","year":"1991","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"key":"10.1016\/j.jconrel.2006.08.004_bib27","first-page":"105","article-title":"Animal models for intranasal drug delivery studies","volume":"2","author":"Gizurarson","year":"1990","journal-title":"Acta Pharm. Nord."},{"key":"10.1016\/j.jconrel.2006.08.004_bib28","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1023\/A:1015884026056","article-title":"Nasal absorption enhancers for biosynthetic human growth hormone in rats","volume":"7","author":"O'Hagan","year":"1990","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2006.08.004_bib29","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1159\/000194301","article-title":"Tracheobronchial function in health and disease. Effect of mucolytic substances","volume":"40","author":"Melville","year":"1980","journal-title":"Respiration"},{"key":"10.1016\/j.jconrel.2006.08.004_bib30","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/jcp.20066","article-title":"N-acetylcysteine inhibits Na+ absorption across human nasal epithelial cells","volume":"201","author":"Rochat","year":"2004","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.jconrel.2006.08.004_bib31","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1023\/A:1014849630520","article-title":"Impact of regional intestinal pH modulation on absorption of peptide drugs: oral absorption studies of salmon calcitonin in beagle dogs","volume":"16","author":"Lee","year":"1999","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2006.08.004_bib32","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1023\/A:1019881706159","article-title":"Insoluble powder formulation as an effective nasal drug delivery system","volume":"19","author":"Ishikawa","year":"2002","journal-title":"Pharm. Res."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365906003786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365906003786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T10:25:22Z","timestamp":1547461522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365906003786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["S0168365906003786"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2006.08.004","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}